Neurocrine Biosciences Stock (NASDAQ:NBIX), Analyst Ratings, Price Targets, Predictions

The latest price target for Neurocrine Biosciences (NASDAQ: NBIX) was reported by Evercore ISI Group on May 14, 2024. The analyst firm set a price target for $175.00 expecting NBIX to rise to within 12 months (a possible 28.53% upside). 63 analyst firms have reported ratings in the last year.

The latest analyst rating for Neurocrine Biosciences (NASDAQ: NBIX) was provided by Evercore ISI Group, and Neurocrine Biosciences initiated their outperform rating.

The last upgrade for Neurocrine Biosciences Inc happened on April 24, 2024 when Wells Fargo raised their price target to $170. Wells Fargo previously had an equal-weight for Neurocrine Biosciences Inc.

The last downgrade for Neurocrine Biosciences Inc happened on November 14, 2022 when Evercore ISI Group changed their price target from $140 to $130 for Neurocrine Biosciences Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurocrine Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurocrine Biosciences was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.

While ratings are subjective and will change, the latest Neurocrine Biosciences (NBIX) rating was a initiated with a price target of $0.00 to $175.00. The current price Neurocrine Biosciences (NBIX) is trading at is $136.15, which is within the analyst’s predicted range.